Oragenics, Inc. (NASDAQ:OGEN) was down 2.2% on Monday . The stock traded as low as $0.43 and last traded at $0.44, approximately 5,797 shares changed hands during mid-day trading. A decline of 99% from the average daily volume of 550,713 shares. The stock had previously closed at $0.45.
The firm has a fifty day moving average price of $0.50 and a two-hundred day moving average price of $0.48.
Oragenics (NASDAQ:OGEN) last announced its quarterly earnings data on Thursday, November 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.01.
About Oragenics (NASDAQ:OGEN)
Oragenics, Inc develops novel antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients.
Read More: Differences Between Momentum Investing and Long Term Investing
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.